2015
Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy
Arnold SV, Li SX, Alexander KP, Spertus JA, Nallamothu BK, Curtis JP, Kosiborod M, Gupta A, Wang TY, Lin H, Dharmarajan K, Strait KM, Lowe TJ, Krumholz HM. Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy. Journal Of The American Heart Association 2015, 4: e002009. PMID: 26077589, PMCID: PMC4599539, DOI: 10.1161/jaha.115.002009.Peer-Reviewed Original ResearchConceptsEarly invasive strategyAnticoagulant strategiesMyocardial infarctionBleeding rateInvasive strategyAcute myocardial infarction patientsOptimal anticoagulant strategyHalf of patientsPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarction patientsHospital use patternsComparative effectiveness studiesRisk-standardized mortalityChoice of anticoagulantsMedian odds ratioCoronary interventionPatient factorsSystemic anticoagulationHospital variabilityInfarction patientsPrincipal diagnosisOdds ratioMultivariate regression modelPatterns of use
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase